Using a Mathematical Modeling To Simulate Pharmacokinetics and Urinary Glucose Excretion of Luseogliflozin and Explore the Role of SGLT1/2 in Renal Glucose Reabsorption
Sign Up to like & getrecommendations! Published in 2022 at "ACS Omega"
DOI: 10.1021/acsomega.2c06483
Abstract: (1) Purpose: To develop a mathematical model combining physiologically based pharmacokinetic and urinary glucose excretion (PBPK-UGE) to simultaneously predict pharmacokinetic (PK) and UGE changes of luseogliflozin (LUS) as well as to explore the role of… read more here.
Keywords: urinary glucose; reabsorption; glucose; explore role ... See more keywords
Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-76256-6
Abstract: This study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin—can be explained in a… read more here.
Keywords: hba1c; urinary glucose; glucose excretion; hba1c reduction ... See more keywords
Clinical and genetic determinants of urinary glucose excretion in patients with diabetes mellitus
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.13417
Abstract: Glucosuria is a representative symptom in diabetes patients with poor glycemic control and in those treated with sodium–glucose cotransporter 2 inhibitors. Renal threshold levels of glucose excretion are known to vary among individuals, but factors… read more here.
Keywords: genetic determinants; glucose excretion; clinical genetic; determinants urinary ... See more keywords